ClinicalTrials.gov
public full text
Public Domain
12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa
12-week, double-blind, placebo-controlled, multicenter, randomized study designed to evaluate the safety and efficacy of 40 mg/day istradefylline compared with placebo in subjects with OFF phenomena advanced PD who were treated with levodopa/carbidopa.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Stalevo in Early Wearing-Off Patients#849076
- Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease#870821
- COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel#1030144
- Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease#1008821
- A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease#967570
Record · ID 1141026
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive